New call-to-action
New call-to-action
New call-to-action

Foundation for Prader-Willi Blog | Clinical Trials (2)

Categories

Harmony Biosciences Initiates Global Phase 3 Study of Pitolisant: TEMPO!

Harmony Biosciences has initiated its Phase 3 study of Pitolisant and is now enrolling individuals with Prader-Willi syndrome ages 6 and up who struggle with excessive daytime sleepiness. Two clinical trial sites are already open and ready to begin s...
April 3, 2024 Read More

Topics: Clinical Trials

VNS4PWS Clinical Trial Opens for Enrollment

The Foundation for Prader-Willi Research is pleased to announce our VNS4PWS clinical trial is now open and enrolling participants with PWS ages 10-40 who experience disruptive behaviors and temper outbursts.
January 8, 2024 Read More

Topics: Research, Clinical Trials

Acadia Initiates Phase 3 COMPASS PWS Study of Carbetocin

Acadia Pharmaceuticals has initiated its pivotal Phase 3 COMPASS PWS study of carbetocin nasal spray (ACP-101) in the United States. COMPASS PWS is a 12-week study evaluating the efficacy and safety of carbetocin nasal spray for hyperphagia in approx...
December 6, 2023 Read More

Topics: Clinical Trials

Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

We are excited to share the news that Soleno has announced positive, statistically significant top-line results from the randomized withdrawal period of study c602 of DCCR for Prader-Willi Syndrome. In the study, patients taking DCCR showed a highly ...
September 26, 2023 Read More

Topics: News, Clinical Trials

Aardvark Announces Rare Disease Designation and Expands Ongoing Phase 2 Trial

Aardvark Therapeutics, a clinical stage biopharmaceutical company, has reported receipt of a Rare Pediatric Disease Designation in Prader-Willi Syndrome (PWS) from the FDA for its lead program ARD-101.
August 3, 2023 Read More

Topics: News, Clinical Trials

Harmony Biosciences Announces Phase 3 Study of Pitolisant

Harmony Biosciences has announced plans to begin a Phase 3 study of Pitolisant for individuals with Prader-Willi syndrome ages 6 and up in the 4th quarter of 2023. This announcement is made following a positive end-of-phase 2 meeting with the FDA. Ha...
July 20, 2023 Read More

Topics: Clinical Trials

PWS Clinical Trials Panel [2022 CONFERENCE VIDEO]

In this 1-hour and 7-minute video, FPWR Executive Director Susan Hedstrom presents an overview of current and upcoming PWS clinical trials, and trial representatives provide brief presentations on specific trials.
July 3, 2023 Read More

Topics: Clinical Trials, Family Conference

What Can I Expect if I Participate in the KITE-PWS Clinical Trial?

KITE-PWS is an ongoing Phase II trial of RGH-706 for people with PWS ages 17 and up. The study is sponsored by Gedeon Richter, a Hungarian-based company with 120 years of drug development experience. They have produced more than 200 drugs in over 40 ...
June 14, 2023 Read More

Topics: Clinical Trials

Acadia Announces Phase 3 Study of ACP-101 (Intranasal Carbetocin)

Acadia Pharmaceuticals has announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for the treatment of hyperphagia in Prader-Willi syndrome (PWS).
June 13, 2023 Read More

Topics: Clinical Trials

About FPWR

The Foundation for Prader-Willi Research (federal tax id 31-1763110) is a nonprofit corporation with federal tax exempt status as a public charity under section 501(c)(3).

4star120x60

NORD_MembershipLogo_Platinum_2021

excellence-in-giving-logo

Main Menu

Our Mission

The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research and therapeutic development.

Contact Us

Foundation for Prader-Willi Research
Phone: 888-322-5487
Email: info@fpwr.org

FPWR
440 N Barranca Ave #3620
Covina, CA 91723

Copyright © 2020. All Rights Reserved. Terms of Use. Privacy Policy. Copyright Infringement Policy. Disclosure Statement.